Open an account

CRISPR Therapeutics AG

CRSP · NASDAQ

$49.88−$0.16 (−0.32%)TodayMarket closed ·
Prev close $50.04

About CRSP

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. The company is headquartered in Zug, Zug. The company went IPO on 2016-10-19. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The firm aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The firm has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The firm product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.

Employees
393
Headquarters
Zug, Zug
Listed
Oct 19, 2016
Sector
Health Care
Industry
Biotechnology
Website
crisprtx.com

CRSP key statistics

Market cap
4.82B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.61M
Volume
2.16M
Open price
$48.52
High today
$50.33
Low today
$47.36
52 Week high
$75.06
52 Week low
$44.12

CRISPR Therapeutics AG (CRSP) at a glance

As of Oct 20, 2026, CRISPR Therapeutics AG (CRSP) shares are priced at $49.88, giving the company a market cap of 4.82B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $47.36 and $50.33. The current price is 5.3% above the day's low and 0.9% below its high.

Volume so far is 2.16M shares, above the average of 1.61M shares a day.

Over the past year CRISPR Therapeutics AG has ranged from $44.12 to $75.06, and now sits 19% of the way up that range.

CRISPR Therapeutics AG met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.94 per share against an estimate of -$1.22.

The average analyst price target is $87.48, 75.4% above the current price, from 13 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

62%of 13 analyst ratings say Buy
  • Buy61.5%
  • Hold38.5%
  • Sell0.0%
Price target · 20 analystsAvg $87.48
Low
$44.44
Now
$49.88
High
$305.55

CRSP earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 27.2% on average.

  1. Q3 FY24: reported -$1.01 per share against an estimate of -$1.44
  2. Q4 FY24: reported -$0.44 per share against an estimate of -$1.19
  3. Q1 FY25: reported -$1.58 per share against an estimate of -$1.28
  4. Q2 FY25: reported -$1.29 per share against an estimate of -$1.45
  5. Q3 FY25: reported -$1.17 per share against an estimate of -$1.29
  6. Q4 FY25: reported -$1.37 per share against an estimate of -$1.18
  7. Q1 FY26: reported -$1.28 per share against an estimate of -$1.25
  8. Q2 FY26: reported -$0.94 per share against an estimate of -$1.22

CRSP news

  • Rishabh Mishra

    Cathie Wood Claps Back After Being Confronted as ARKK Fell Nearly 15% While QQQ Soared 112% in Five Years — Calls It an ‘Incorrect Comparison’

  • Rishabh Mishra

    Cathie Wood Says AI Revolution Could Supercharge Global Growth — TSLA, COIN and CRSP Stocks Are Among Her Top Bets

  • Chandrima Sanyal

    Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs

  • Mohd Haider

    Recursion, Novavax and Crispr Stocks Trending in Pre-Market—Here's Why

  • Mohd Haider

    Moderna Stock Cools Off After-Hours, Following Massive 177% Cancer Vaccine Rally — Merck, Pfizer and BioNTech Among mRNA Names Trending Tonight

  • Crispus Nyaga

    Investors Flee Cathie Wood's ARKK ETF As It Trails S&P 500, Nasdaq 100 By Far

  • Press releasePRNewswire

    A Unique Klotho-based Anti-Aging Therapy to Be Introduced at a Premier Longevity Forum: Inside Avaí Bio's Cell-Based Platform Approach

  • Press releaseGlobe Newswire

    Legendary Investors are Rotating Capital into AI Powered Biotech

Similar companies

Companies in the same industry as CRISPR Therapeutics AG

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.